Institutional Perspectives in Neurology: Multiple Sclerosis

Jessica L. Stulc, MD, MPH, offered an in-depth review of the latest approved therapies in the sphingosine phosphate 1 targeting class of oral medications for MS including ozanimod (Zeposia; BMS) and ponesimod (Ponvory; Janssen).

The associate professor of neurology at Mayo Clinic Rochester discusses technological advancements and research efforts in relation to differential multiple sclerosis.

The associate professor of neurology at Mayo Clinic Rochester, commented on biomarkers for identifying MS in patients, as well as the significance of new MS consensus guidelines.

The associate professor of neurology at Mayo Clinic Rochester discusses the importance of alternative diagnoses and rarer presentations of MS, in order to avoid misdiagnoses and inappropriate treatment for patients.

Chaired by Brian G. Weinshenker, MD, the presentations also feature Mayo Clinic experts W. Oliver Tobin, MBBCh, BAO, PhD; Jessica Stulc, MD, MPH; and Orhun H. Kantarci, MD. [WATCH TIME: 1 hour, 30 minutes]